CRISPR Therapeutics (CRSP) Stock Plunges 10% as Cathie Wood’s ARK Invest Scoops Up Shares

Key Highlights

• ARK Invest acquired approximately 281,000 shares of CRSP valued at roughly $14.82M following a 10% price decline
• A $350M private placement announcement by CRISPR Therapeutics sparked the selloff
• CRSP ranks as ARK’s second-biggest position across all ETFs, representing approximately $500M in total holdings
• ARK reduced stakes in 10x Genomics (TXG) and Teradyne (TER) during portfolio rebalancing
• Both Seeking Alpha Quant ratings and Wall Street consensus assign CRSP a Buy recommendation

Shares of CRISPR Therapeutics (CRSP) tumbled approximately 10% following the biotech firm’s disclosure of a $350M private placement. Cathie Wood’s ARK Invest responded by accumulating shares at the lower price point.

CRISPR Therapeutics AG, CRSP

According to ARK’s March 11, 2026 daily transaction summary, the investment firm accumulated roughly 281,000 shares of CRSP across its exchange-traded fund suite, representing approximately $14.82M in value.

This purchase follows an established pattern. During the fourth quarter of 2025, Wood expanded ARK’s CRSP holdings by 7.5%, acquiring approximately 735,000 shares. The recent transaction maintains this upward trajectory.

Within ARK’s combined ETF portfolio, CRSP now occupies the second-largest position, accounting for a 4.49% weighting and approximately $500M in aggregate exposure. This represents substantial conviction in a company still in pre-revenue stage.

Private Placement Triggers Investor Reaction

The double-digit percentage decline occurred after CRISPR Therapeutics disclosed plans for a $350M private capital raise. Such transactions typically pressure share prices temporarily due to ownership dilution concerns among existing shareholders.

The financing move aligns with CRISPR Therapeutics’ operational reality. As a company without current revenue generation and negative operating margins, securing capital to advance its development pipeline remains essential to the business strategy.

Financial fundamentals provide some reassurance — the company maintains a current ratio of 13.32 alongside a minimal debt-to-equity ratio of 0.11, indicating robust liquidity positioning and conservative leverage.

These balance sheet metrics likely factored into ARK’s decision to increase exposure following the price decline.

CRISPR Therapeutics’ Development Portfolio

Casgevy, CRISPR Therapeutics’ inaugural commercialized therapy developed in partnership with Vertex Pharmaceuticals, addresses sickle-cell disease and transfusion-dependent beta-thalassemia.

The company’s pipeline extends beyond Casgevy, encompassing programs in immuno-oncology, cardiovascular applications, and stem cell-derived treatments for Type 1 diabetes management.

Current market capitalization stands at approximately $5.07 billion based on recent valuations.

Insider transaction patterns show a clear direction — five separate insider sales totaling 163,751 shares occurred during the previous three months, with zero insider purchase activity recorded.

Portfolio Adjustments Across ARK’s Holdings

While accumulating CRSP shares, ARK simultaneously reduced exposure elsewhere. The firm divested 78,412 shares of 10x Genomics (TXG) valued at approximately $1.60M and sold 21,505 shares of Teradyne (TER) worth $6.47M.

These transactions reflect standard portfolio management practices across ARK’s actively managed ETF offerings rather than signaling negative sentiment toward those particular companies.

Analyst perspectives on CRSP remain constructive, with Buy ratings from both Seeking Alpha’s Quant rating system and Wall Street analyst consensus. The Quant methodology particularly highlights strength in growth and momentum categories.

A Seeking Alpha analyst highlighted Casgevy’s market introduction and the company’s cash position as positive factors, while acknowledging inherent risks associated with pre-revenue biotechnology investments.

GuruFocus’ GF Value assessment currently indicates significant overvaluation at $16.13, presenting a contrasting viewpoint to the prevailing bullish analyst outlook.

CRSP shares declined approximately 10.17% on the session when the capital raise was announced.

The post CRISPR Therapeutics (CRSP) Stock Plunges 10% as Cathie Wood’s ARK Invest Scoops Up Shares appeared first on Blockonomi.